Guilin Layn Natural Ingredients Corp.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guilin Rhine Biotechnology Co., Ltd. was established in 2000 and is a technology-based and export-oriented private enterprise specializing in the research and development, production, and sales of natural health products. The company has more than 20 years of experience in the plant extraction industry, and is a leading enterprise in the global plant extraction industry. It is also the first listed company in the domestic plant extraction industry. In 2021, it was awarded the title of "Little Giant" at the national level, specializing in precision and innovation. The company is committed to building a globally leading natural health product platform, improving people's health levels, and making life better! The fourth generation natural extract production base of the company covers an area of about 300 acres, with advanced production equipment and automated intelligent extraction production lines that meet GMP standards. The annual processing capacity of raw materials can reach over 60000 tons. The company has passed multiple certifications such as GMP, HACCP, ISO, etc., and multiple products have certificates such as KOSHER, HALAL, ORGANIC, SC, FSSC22000, etc. Among them, Siraitia grosvenorii glycoside and stevioside both passed the US FDA GRAS certification in 2011, which is the first enterprise in the world to obtain the certification of both products. The company's products are widely used in the fields of food and beverage, medicine, health products, cosmetics, pet products, feed, etc., and are exported to more than 60 countries and regions around the world, such as the United States, Europe, South Korea, and Japan. In 2020, the company's strategic upgrade took advantage of historical opportunities to expand its industrial cannabis industry in the United States, investing nearly 80 million US dollars in the construction of the "Industrial Cannabis Extraction and Application Engineering Construction Project". The project was officially put into operation on October 1, 2021, and was listed by the Indiana government as a demonstration project in the field of industrial cannabis extraction in the United States. On the other hand, we have carried out horizontal mergers and acquisitions of high-quality assets in the same industry, successfully acquiring 51% equity of Chengdu Huagao Biological Products Co., Ltd., obtaining a controlling stake in Huagao Biological, further promoting the implementation of the company's "big single product" development strategy, and becoming a leader in the global tea extraction industry. As a pioneer in the plant extraction industry, Rhine Bio has strong technological research and development capabilities. The company's technology center has been recognized as the Guangxi Autonomous Region level enterprise technology center, and has research and development platforms such as postdoctoral research workstation, Guangxi academician workstation, Guangxi Autonomous Region level engineering technology center, Luohanguo Engineering Research Institute, etc. As of March 2023, the company has 85 national invention patents and 6 PCTs, and has mastered core technologies for extracting over 300 natural ingredients. It has also established four major marketing centers covering the world on the sales end, with independent research and development platforms and sales teams, as well as independent third-party testing laboratories. It is one of the few enterprises in the plant extraction industry that has a full industry chain platform. Looking forward to the future, the company will adhere to the business philosophy of "green technology, healthy future", closely revolve around the vision of building a global leading natural health product platform, continue to increase investment or mergers and acquisitions in upstream and downstream related businesses, focus on the development and construction of raw material bases, build functional food and beverage, dietary supplements, cosmetics, and medicine downstream industries' brand and channel operation platforms, and form a complete industrial chain ecological closed-loop, Build the company into a new type of health consumer goods enterprise and make due contributions to the implementation of the "Healthy China 2030" action plan!. |
| Headquarter | Guilin |
| Establish Date | 11/28/2000 |
| Listed Code | 002166.SZ |
| Listed Date | 9/13/2007 |
| Chairman | Qin Benjun. |
| CEO | Qin Benjun. |
| Website | www.layn.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
